SCHEMBL2479238

SCHEMBL2479238

NCc1ccncc1C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 11/20 0.53
KDM6B O15054 6/20 0.53
TDP1 Q9NUW8 2/20 0.53
KDM4E B2RXH2 2/20 0.53
KDM4A O75164 2/20 0.53
KDM4D Q6B0I6 2/20 0.53
MEN1 O00255 1/20 0.53
ALDH1A1 P00352 1/20 0.53
MAPT P10636 1/20 0.53
THRB P10828 1/20 0.53
KMT2A Q03164 1/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
AOC1 P19801 7/20 0.52
AOC3 Q16853 7/20 0.52
LOXL2 Q9Y4K0 1/20 0.50
SIRT3 Q9NTG7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL3973104 0.90 LOXL2 (0.46) KDM4CKDM6BTDP1KDM4EKDM4A
SCHEMBL30465694 0.82 KDM4C (0.51) KDM4CKDM6BTDP1KDM4EKDM4A
SCHEMBL123203 0.82 KDM4C (0.51) KDM4CKDM6BTDP1KDM4EKDM4A
SCHEMBL3880004 0.82 KDM4C (0.50) KDM4CKDM6BTDP1KDM4EKDM4A
SCHEMBL3931892 0.81 KDM4C (0.48) KDM4CKDM6BTDP1KDM4EKDM4A
SCHEMBL6207070 0.81 KDM4C (0.48) KDM4CKDM6BTDP1KDM4EKDM4A
SCHEMBL7509912 0.81 KDM4C (0.48) KDM4CKDM6BTDP1KDM4EKDM4A
SCHEMBL7263236 0.81 KDM4C (0.48) KDM4CKDM6BTDP1KDM4EKDM4A
Acetic Acid SCHEMBL16666943 0.79 KDM4C (0.49) KDM4CKDM6BTDP1KDM4EKDM4A
SCHEMBL9858541 0.79 KDM4C (0.47) KDM4CKDM6BTDP1KDM4EKDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3089746-A1 THERAPEUTIC INHIBITORY COMPOUNDS Lifesci Pharmaceuticals, Inc. (BB) 2016-11-09 EP disclosed
WO-2015103317-A1 THERAPEUTIC INHIBITORY COMPOUNDS LIFESCI PHARMACEUTICALS, INC. (BB) 2015-07-09 WO disclosed
US-20110319411-A1 ISOINDOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTIS PHARMACEUTICALS, INC. (US) 2011-12-29 US disclosed
EP-2373645-A1 ISOINDOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS Sirtris Pharmaceuticals, Inc. (US) 2011-10-12 EP disclosed
WO-2010077686-A1 ISOINDOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319411-A1 ISOINDOLINONE AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 KDM4C 4006/4885KDM6B 3302/4885TDP1 716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.